Cassava Sciences Reports Top-Line Results Of Two-Year Clinical Safety Study Of Simufilam, Investigational Oral Drug For Treatment Of Alzheimer's Disease
Cassava Sciences Reports Top-Line Results Of Two-Year Clinical Safety Study Of Simufilam, Investigational Oral Drug For Treatment Of Alzheimer's Disease
Cassava Sciences报告了为期两年的Simufilam临床安全性研究的主要结果，Simufilam是治疗阿尔茨海默氏病的在研口服药物
-
ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer's Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.
-
Mild Alzheimer's Patients Who Received Simufilam Non-Continuously Declined a Group Average of 1 Point on ADAS-Cog, Baseline to Month 24.
- Oral Simufilam Safe, Well-Tolerated.
- 在基线至第24个月持续接受候选药物Simufilam治疗的一组轻度阿尔茨海默氏症患者中，ADAS-Cog分数保持稳定。
- 非连续接受Simufilam治疗的轻度阿尔茨海默氏症患者在ADAS-Cog上平均下降了1分，基线为第24个月。
- 口服 Simufilam 安全，耐受性良好。